BDRX — Biodexa Pharmaceuticals Share News
0.000.00%
Last trade - 00:00NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:38 PM
NASDAQ RESUMED AT 09:36 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
Brief: Biodexa Announces Enrolment Of First European Patients Into Pivotal Phase 3 Serenta Trial In FAP
Brief: Biodexa Pharmaceuticals PLC Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Biodexa Announces Activation Of First Clinical Study Site For Phase 3 Trial In Familial Adenomatous Polyposis
Brief: Biodexa Receives Orphan Drug Designation In Europe For eRapa In FAP
Biodexa rises on FDA's 'fast track' tag for rare disease drug
Brief: Biodexa Pharmaceuticals Ratio Change On American Depositary Receipts To New Ratio Of 1 ADR Representing 10,000 Shares
Brief: Biodexa Closes $5 Mln Registered Direct Offering, Concurrent Private Placement
Brief: Biodexa Announces Positive Phase 2 Clinical Trial Results Of Erapa™ At 12 Months In Familial Adenomatous Polyposis
Brief: Biodexa Pharmaceuticals Provides Preliminary Results For Year 2023
Brief: Biodexa Says Co's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
Brief: Biodexa Pharmaceuticals Files For Offering Of Up To 1.3 Mln Ordinary Shares By The Selling Shareholders
Brief: Midatech Pharma PLC Files For Resale Of Up To 2.17 Billion Ordinary Shares Representing 86.8 Million Adss By Selling Shareholders - SEC Filing
Midatech: Surges on positive pipeline and operational updates
Midatech Pharma jumps as dosage study of brain tumor treatment meets main goal
Midatech: Eyes best day in 17 months on joint research into drug delivery platform
NASDAQ RESUMED AT 08:47 AM